Nintedanibesilat Stada D.O.O.

Nintedanib, the active ingredient in Nintedanibesilat Stada D.O.O., is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It is used to treat fibrotic lung conditions such as idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients.

GNH USA supplies Nintedanibesilat Stada D.O.O. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is an antifibrotic agent that targets pathways involved in lung fibrosis. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: mitigates fibrotic changes and helps preserve respiratory capacity. - Progressive fibrosing interstitial lung disease (when approved): may delay worsening of lung function.

Nintedanib may cause a range of adverse reactions, most of which are manageable with monitoring and supportive care.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Vomiting: occasional expulsion of stomach contents. - Abdominal pain: discomfort or cramps in the stomach area. - Decreased appetite: reduced desire to eat. - Weight loss: unintended loss of body weight.

Serious or Rare Side Effects: - Elevated liver enzymes: may indicate hepatic injury. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: rare cases of myocardial infarction or stroke. - Severe infections: opportunistic infections in immunocompromised patients. - Gastrointestinal perforation: rare but serious tearing of the GI tract. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks. - Liver monitoring: perform baseline and periodic liver function tests. - Bleeding risk: evaluate concomitant anticoagulant or antiplatelet use. - Cardiovascular assessment: review history of heart disease or stroke. - Gastrointestinal management: advise patients to stay hydrated and report persistent diarrhea. - Pregnancy and lactation: avoid use in pregnancy; safety in breastfeeding is unknown. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Nintedanib can interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive bleeding potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise drug levels. - P‑glycoprotein inhibitors (e.g., verapamil): could affect absorption. - Diuretics: monitor for dehydration if gastrointestinal losses occur.